002422 科伦药业
已收盘 08-21 15:00:00
资讯
新帖
简况
科伦博泰生物中期业绩亮眼:归母净利润达3.88亿元人民币
投资观察 · 08-17
科伦博泰生物中期业绩亮眼:归母净利润达3.88亿元人民币
科伦药业新注册《科伦药业CRM客户管理系统1.0》项目的软件著作权
证券之星 · 08-11
科伦药业新注册《科伦药业CRM客户管理系统1.0》项目的软件著作权
科伦药业新注册《科伦药业文献管理系统1.0》项目的软件著作权
证券之星 · 08-08
科伦药业新注册《科伦药业文献管理系统1.0》项目的软件著作权
股市必读:科伦药业新发布《关于公司控股股东部分股份质押及解除质押的公告》
证券之星 · 08-06
股市必读:科伦药业新发布《关于公司控股股东部分股份质押及解除质押的公告》
科伦药业(002422)披露回购公司股份进展公告,8月4日股价上涨2.32%
证券之星 · 08-04
科伦药业(002422)披露回购公司股份进展公告,8月4日股价上涨2.32%
科伦药业最新公告:参与第十二批全国药品集中采购拟中标14个品种
证券之星 · 08-02
科伦药业最新公告:参与第十二批全国药品集中采购拟中标14个品种
科伦药业(002422.SZ):TROP2 ADC芦康沙妥珠单抗(sac-TMT)新增适应症上市申请获受理
智通财经 · 07-30
科伦药业(002422.SZ):TROP2 ADC芦康沙妥珠单抗(sac-TMT)新增适应症上市申请获受理
科伦博泰获NMPA临床试验批准,SKB565用于治疗晚期实体瘤
投资观察 · 07-27
科伦博泰获NMPA临床试验批准,SKB565用于治疗晚期实体瘤
科伦药业最新公告:子公司SKB565新药临床试验申请获国家药监局批准
证券之星 · 07-27
科伦药业最新公告:子公司SKB565新药临床试验申请获国家药监局批准
中欧基金葛兰二季报出炉:君实生物首进持仓前十,科伦药业获大举增持
澎湃新闻 · 07-21
中欧基金葛兰二季报出炉:君实生物首进持仓前十,科伦药业获大举增持
7月20日科伦药业涨6.44%,红土创新医疗保健股票A基金重仓该股
证券之星 · 07-20
7月20日科伦药业涨6.44%,红土创新医疗保健股票A基金重仓该股
股市必读:7月16日科伦药业现1.51亿元大宗交易
证券之星 · 07-17
股市必读:7月16日科伦药业现1.51亿元大宗交易
科伦药业(002422)披露主体信用评级结果,7月16日股价上涨1.69%
证券之星 · 07-16
科伦药业(002422)披露主体信用评级结果,7月16日股价上涨1.69%
科伦药业(002422)披露子公司TROP2 ADC联合疗法3期临床达主要终点,7月15日股价上涨1.18%
证券之星 · 07-15
科伦药业(002422)披露子公司TROP2 ADC联合疗法3期临床达主要终点,7月15日股价上涨1.18%
科伦药业涨8.26%,东海证券二个月前给出“买入”评级
证券之星 · 07-14
科伦药业涨8.26%,东海证券二个月前给出“买入”评级
研报掘金丨浙商证券:维持科伦药业“买入”评级,看好创新驱动下经营和业绩向上拐点
格隆汇 · 07-06
研报掘金丨浙商证券:维持科伦药业“买入”评级,看好创新驱动下经营和业绩向上拐点
7月3日科伦药业涨7.22%,中欧医疗健康混合A基金重仓该股
证券之星 · 07-03
7月3日科伦药业涨7.22%,中欧医疗健康混合A基金重仓该股
科伦药业(002422)披露回购公司股份进展公告,7月1日股价上涨8.9%
证券之星 · 07-01
科伦药业(002422)披露回购公司股份进展公告,7月1日股价上涨8.9%
科伦药业涨8.90%,东海证券二个月前给出“买入”评级
证券之星 · 07-01
科伦药业涨8.90%,东海证券二个月前给出“买入”评级
6月29日科伦药业涨10.00%,中欧医疗健康混合A基金重仓该股
证券之星 · 06-29
6月29日科伦药业涨10.00%,中欧医疗健康混合A基金重仓该股
加载更多
公司概况
公司名称:
四川科伦药业股份有限公司
所属行业:
医药制造业
上市日期:
2010-06-03
主营业务:
四川科伦药业股份有限公司的主营业务是输液产品及非输液医药产品的研发、生产和销售。公司的主要产品是大容量注射剂(输液)、小容量注射剂(水针)、注射用无菌粉针(含分装粉针及冻干粉针)、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等。公司是国家大容量注射剂工程技术研究中心、生物靶向药物国家工程研究中心等多个国家创新平台。
发行价格:
83.36
{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"科伦药业","latestPrice":44.87,"timestamp":1787295813000,"preClose":47.15,"halted":0,"volume":29197395,"delay":0,"changeRate":-0.0484,"floatShares":1299000000,"shares":1591000000,"eps":0.9879,"marketStatus":"已收盘","change":-2.28,"latestTime":"08-21 15:00:00","open":45.9,"high":46.58,"low":44.49,"amount":1323000000,"amplitude":0.0443,"askPrice":44.87,"askSize":1623,"bidPrice":44.86,"bidSize":17,"shortable":0,"etf":0,"ttmEps":0.9879,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":5,"adr":0,"adjPreClose":47.15,"symbolType":"stock","openAndCloseTimeList":[[1787275800000,1787283000000],[1787288400000,1787295600000]],"highLimit":51.87,"lowLimit":42.44,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1590781208,"isCdr":false,"pbRate":3.04,"roa":"--","peRate":45.419577,"roe":"1.86%","epsLYR":1.07,"committee":-0.929145,"marketValue":71378000000,"turnoverRate":0.0225,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-08-24。","floatMarketCap":58269000000},"requestUrl":"/m/hq/s/002422","defaultTab":"news","newsList":[{"id":"1136932387","title":"科伦博泰生物中期业绩亮眼:归母净利润达3.88亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1136932387","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136932387?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:27","pubTimestamp":1786966033,"startTime":"0","endTime":"0","summary":"8月17日,据路透社报道,四川科伦博泰生物医药股份有限公司(简称“科伦博泰生物”)公布其上半年财务表现。数据显示,该公司报告期内归属于母公司股东的净利润达到3.88亿元人民币,彰显出强劲的盈利增长势头。这一业绩成果不仅反映了公司在生物医药领域的深耕成效,也为其未来发展奠定了坚实基础。作为科伦药业(002422)旗下的重要生物制药平台,科伦博泰生物(06990)凭借持续的技术创新与产品管线拓展,正稳步提升市场竞争力。此次中期业绩的公布,无疑为投资者提供了积极信号,进一步巩固了市场对其长期价值的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU2148510915.USD","LU1979443071.USD","002422","BK1161","BK0239","LU1934453819.USD","LU0196878994.USD","BK0060","06990","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658195569","title":"科伦药业新注册《科伦药业CRM客户管理系统1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2658195569","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658195569?lang=zh_cn&edition=full","pubTime":"2026-08-11 02:22","pubTimestamp":1786386132,"startTime":"0","endTime":"0","summary":"证券之星消息,近日科伦药业(002422)新注册了《科伦药业CRM客户管理系统1.0》项目的软件著作权。今年以来科伦药业新注册软件著作权2个。结合公司2025年年报财务数据,2025年公司在研发方面投入了22.05亿元,同比增1.6%。通过天眼查大数据分析,四川科伦药业股份有限公司共对外投资了47家企业,参与招投标项目8817次;财产线索方面有商标信息1206条,专利信息2081条,著作权信息16条;此外企业还拥有行政许可1368个。数据来源:天眼查APP以上内容为证券之星据公开信息整理,不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100001867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","159180","002422","LU1979443071.USD","BK0239","LU1934453819.USD","BK0060","LU2148510915.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657233566","title":"科伦药业新注册《科伦药业文献管理系统1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2657233566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657233566?lang=zh_cn&edition=full","pubTime":"2026-08-08 02:23","pubTimestamp":1786126990,"startTime":"0","endTime":"0","summary":"证券之星消息,近日科伦药业(002422)新注册了《科伦药业文献管理系统1.0》项目的软件著作权。今年以来科伦药业新注册软件著作权1个。结合公司2025年年报财务数据,2025年公司在研发方面投入了22.05亿元,同比增1.6%。通过天眼查大数据分析,四川科伦药业股份有限公司共对外投资了47家企业,参与招投标项目8817次;财产线索方面有商标信息1206条,专利信息2081条,著作权信息16条;此外企业还拥有行政许可1368个。数据来源:天眼查APP以上内容为证券之星据公开信息整理,不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080800001147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159180","LU2148510915.USD","LU1934453819.USD","LU1979443071.USD","LU1064131003.USD","BK0239","LU1064130708.USD","002422","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657212995","title":"股市必读:科伦药业新发布《关于公司控股股东部分股份质押及解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657212995","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657212995?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:45","pubTimestamp":1785951916,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘,科伦药业报收于42.9元,上涨1.44%,换手率1.97%,成交量25.62万手,成交额10.99亿元。公司公告汇总关于公司控股股东部分股份质押及解除质押的公告四川科伦药业股份有限公司控股股东刘革新先生近日办理了部分股份解除质押及新质押业务。本次解除质押9,167,000股,占其所持股份比例2.42%,占公司总股本0.58%;同时新质押6,900,000股,占其所持股份比例1.82%,占公司总股本0.43%,质押用途为个人资金需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU1064130708.USD","LU2148510915.USD","BK0239","002422","LU1979443071.USD","LU1934453819.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656053119","title":"科伦药业(002422)披露回购公司股份进展公告,8月4日股价上涨2.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656053119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656053119?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:47","pubTimestamp":1785836863,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,科伦药业报收于42.29元,较前一交易日上涨2.32%,最新总市值为672.74亿元。该股当日开盘42.0元,最高42.97元,最低41.66元,成交额达11.28亿元,换手率为2.05%。科伦药业于2026年8月4日披露《关于回购公司股份进展的公告》。本次回购符合相关法规及既定方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400029712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","LU1979443071.USD","002422","BK0239","LU1934453819.USD","BK0060","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656127473","title":"科伦药业最新公告:参与第十二批全国药品集中采购拟中标14个品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2656127473","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656127473?lang=zh_cn&edition=full","pubTime":"2026-08-02 16:19","pubTimestamp":1785658769,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称,公司及子公司参加了国家组织药品联合采购办公室组织的第十二批全国药品集中采购的投标工作,沙库巴曲缬沙坦钠片、脂肪乳注射液等14个品种拟中标。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200006697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","LU1979443071.USD","002422","BK0060","LU1064131003.USD","LU1934453819.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655712728","title":"科伦药业(002422.SZ):TROP2 ADC芦康沙妥珠单抗(sac-TMT)新增适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655712728","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655712728?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:31","pubTimestamp":1785411100,"startTime":"0","endTime":"0","summary":"此前,芦康沙妥珠单抗用于一线治疗不可手术切除的局部晚期、复发或转移性PD-L1阴性TNBC已获NMPA授予突破性疗法认定。本次新增适应症上市申请亦已纳入优先审评审批程序,成为芦康沙妥珠单抗纳入该程序的第六项上市申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","ADC","LU2148510915.USD","BK0239","BK4231","IPOS","LU1064130708.USD","BK0060","002422","LU1979443071.USD","LU1064131003.USD","NETL","LU1934453819.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159541447","title":"科伦博泰获NMPA临床试验批准,SKB565用于治疗晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1159541447","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159541447?lang=zh_cn&edition=full","pubTime":"2026-07-27 21:36","pubTimestamp":1785159417,"startTime":"0","endTime":"0","summary":"科伦博泰生物(6990.HK)近日迎来重大利好。该公司自主研发的候选药物SKB565,已正式获得中国国家药品监督管理局(NMPA)的临床试验默示许可(IND)。此次获批的适应症,是针对晚期实体瘤的治疗。\n这笔临床试验的批准,无疑为科伦博泰的研发管线注入了新的活力。SKB565作为一款在研药物,其未来的临床进展值得市场关注。目前,围绕该药物的更多细节,仍有待公司后续进一步披露。\n此次IND获批,是科伦博泰在肿瘤治疗领域布局的又一重要里程碑。随着临床试验的推进,SKB565能否在众多同类药物中脱颖而出,展现出优异的疗效与安全性,将直接决定其未来的市场潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934453819.USD","LU1064131003.USD","LU1064130708.USD","LU0196878994.USD","LU2148510915.USD","BK0239","002422","06990","LU1979443071.USD","BK1161","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654255014","title":"科伦药业最新公告:子公司SKB565新药临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654255014","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654255014?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:10","pubTimestamp":1785150636,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称,公司控股子公司科伦博泰收到国家药监局药品审评中心同意新型双载荷ADC药物SKB565新药临床试验申请的临床试验通知书,用于治疗晚期实体瘤。SKB565是科伦博泰首个进入临床阶段的双载荷抗体偶联药物,采用创新性双载荷设计,具有双重抗肿瘤机制。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700028004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1934453819.USD","BK0239","002422","LU1064131003.USD","LU1979443071.USD","BK0060","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653208394","title":"中欧基金葛兰二季报出炉:君实生物首进持仓前十,科伦药业获大举增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2653208394","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653208394?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:28","pubTimestamp":1784636880,"startTime":"0","endTime":"0","summary":"2026年二季度期间,中欧基金投资总监葛兰旗下两只医药主题基金均逆势跑赢基准。澎湃新闻记者 丁欣晴\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-21/doc-iniiqquw9179532.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-21/doc-iniiqquw9179532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2148510915.USD","BK0239","BK1161","LU1064131003.USD","002422","BK1515","BK1583","LU1934453819.USD","LU1064130708.USD","BK0060","01877","LU1979443071.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652263296","title":"7月20日科伦药业涨6.44%,红土创新医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652263296","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652263296?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:40","pubTimestamp":1784536831,"startTime":"0","endTime":"0","summary":"证券之星消息,7月20日科伦药业涨6.44%,收盘报47.8元,换手率4.47%,成交量58.0万手,成交额27.17亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为红土创新基金的红土创新医疗保健股票A。红土创新医疗保健股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","LU1064131003.USD","002422","LU1934453819.USD","LU1064130708.USD","BK0060","LU1979443071.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652426375","title":"股市必读:7月16日科伦药业现1.51亿元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2652426375","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652426375?lang=zh_cn&edition=full","pubTime":"2026-07-17 01:09","pubTimestamp":1784221748,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘,科伦药业报收于49.9元,上涨1.69%,换手率4.9%,成交量63.7万手,成交额31.07亿元。当日关注点交易信息汇总:7月16日科伦药业主力资金净流入1287.88万元。大宗交易7月16日科伦药业现1.51亿元大宗交易。联合资信出具《四川科伦药业股份有限公司主体长期信用评级报告》,评定公司主体信用等级为AAA,评级展望为稳定,有效期为2026年7月16日至2027年7月15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700000649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","002422","LU1979443071.USD","BK0239","LU1934453819.USD","BK0060","LU2148510915.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651701440","title":"科伦药业(002422)披露主体信用评级结果,7月16日股价上涨1.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651701440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651701440?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:20","pubTimestamp":1784211629,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘,科伦药业报收于49.9元,较前一交易日上涨1.69%,最新总市值为793.8亿元。该股当日开盘47.5元,最高51.46元,最低46.02元,成交额达31.07亿元,换手率为4.9%。近日,科伦药业披露《关于主体信用评级结果的公告》。联合资信出具《四川科伦药业股份有限公司主体长期信用评级报告》,评定公司主体信用等级为AAA,评级展望为稳定,有效期为2026年7月16日至2027年7月15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651645648","title":"科伦药业(002422)披露子公司TROP2 ADC联合疗法3期临床达主要终点,7月15日股价上涨1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651645648","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651645648?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:23","pubTimestamp":1784107392,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘,科伦药业报收于49.07元,较前一交易日上涨1.18%,最新总市值为780.6亿元。该股当日开盘47.04元,最高52.72元,最低47.01元,成交额达42.08亿元,换手率为6.43%。科伦药业于近日披露公告,其控股子公司科伦博泰研发的TROP2 ADC药物芦康沙妥珠单抗联合帕博利珠单抗,在治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的3期临床研究OptiTROP-Lung06中,达到无进展生存期主要终点。该联合方案此前已在PD-L1阳性人群中取得阳性结果,并已提交上市申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500032839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","002422","BK0239","BK0060","LU2148510915.USD","LU1064130708.USD","LU1934453819.USD","LU1979443071.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651173041","title":"科伦药业涨8.26%,东海证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651173041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651173041?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:27","pubTimestamp":1784017630,"startTime":"0","endTime":"0","summary":"今日科伦药业涨8.26%,收盘报48.5元。2026年4月15日,东海证券研究员杜永宏,付婷发布了对科伦药业的研报《公司简评报告:传统主业企稳可期,创新商业化快速推进》,该研报对科伦药业给出“买入”评级。公司输液和中间体及原料药业务有望企稳向上,创新产品快速放量,维持“买入”评级。科伦药业个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400030721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649645179","title":"研报掘金丨浙商证券:维持科伦药业“买入”评级,看好创新驱动下经营和业绩向上拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2649645179","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649645179?lang=zh_cn&edition=full","pubTime":"2026-07-06 14:09","pubTimestamp":1783318173,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0276","LU1979443071.USD","LU1934453819.USD","601878","LU1064130708.USD","BK0239","LU1064131003.USD","LU2148510915.USD","BK0060","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648652680","title":"7月3日科伦药业涨7.22%,中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648652680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648652680?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:41","pubTimestamp":1783068092,"startTime":"0","endTime":"0","summary":"证券之星消息,7月3日科伦药业涨7.22%创60日新高,收盘报47.98元,换手率4.13%,成交量53.66万手,成交额24.17亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共109家,其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元,最新净值1.9354,较上一交易日上涨0.32%,近一年上涨13.06%。中欧医疗健康混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","002422","LU1979443071.USD","159760","LU1934453819.USD","LU1064130708.USD","BK0239","BK0060","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648549143","title":"科伦药业(002422)披露回购公司股份进展公告,7月1日股价上涨8.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648549143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648549143?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:12","pubTimestamp":1782915143,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘,科伦药业报收于41.95元,较前一交易日上涨8.9%,最新总市值为667.33亿元。该股当日开盘38.52元,最高42.37元,最低36.92元,成交额达20.14亿元,换手率为3.86%。近日,科伦药业发布《关于回购公司股份进展的公告》。公告显示,公司于2026年1月4日审议通过回购股份方案,拟通过集中竞价方式回购股份,回购价格上限由35元/股调整为34.53元/股,自2026年5月11日起生效;回购资金总额不低于5,000.00万元且不超过10,000.00万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0060","BK0239","LU1064131003.USD","002422","LU2148510915.USD","LU1979443071.USD","LU1934453819.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648351668","title":"科伦药业涨8.90%,东海证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2648351668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648351668?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:47","pubTimestamp":1782895630,"startTime":"0","endTime":"0","summary":"今日科伦药业涨8.90%,收盘报41.95元。2026年4月15日,东海证券研究员杜永宏,付婷发布了对科伦药业的研报《公司简评报告:传统主业企稳可期,创新商业化快速推进》,该研报对科伦药业给出“买入”评级。公司输液和中间体及原料药业务有望企稳向上,创新产品快速放量,维持“买入”评级。科伦药业个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322395","title":"6月29日科伦药业涨10.00%,中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647322395?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:42","pubTimestamp":1782722565,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日科伦药业涨10.00%,收盘报39.16元,换手率2.35%,成交量30.48万手,成交额11.73亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共109家,其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元,最新净值1.703,较上一交易日下跌1.34%,近一年上涨2.14%。中欧医疗健康混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","002422","LU1979443071.USD","BK0239","BK0060","159760","LU1934453819.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787345034540,"stockEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0884},{"period":"3month","weight":0.2923},{"period":"6month","weight":0.4418},{"period":"1year","weight":0.2093},{"period":"ytd","weight":0.5503}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0099},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0433},{"period":"1year","weight":0.0356},{"period":"ytd","weight":-0.016}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41048人(较上一季度减少6.85%)","perCapita":"31636股","listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","registeredCapital":"159078万元","survey":" 四川科伦药业股份有限公司的主营业务是输液产品及非输液医药产品的研发、生产和销售。公司的主要产品是大容量注射剂(输液)、小容量注射剂(水针)、注射用无菌粉针(含分装粉针及冻干粉针)、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等。公司是国家大容量注射剂工程技术研究中心、生物靶向药物国家工程研究中心等多个国家创新平台。","listedPrice":83.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦药业,002422,科伦药业股票,科伦药业股票老虎,科伦药业股票老虎国际,科伦药业行情,科伦药业股票行情,科伦药业股价,科伦药业股市,科伦药业股票价格,科伦药业股票交易,科伦药业股票购买,科伦药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}